G1 Therapeutics' Cosela (trilaciclib) Receives US FDA's Approval as the First Myeloprotection Therapy for Extensive-Stage Small Cell Lung Cancer
Shots:
- The approval is based on three clinical trials involves assessing Trilaciclib +carboplatin/etoposide (+/- atezolizumab) and topotecan CT regimens in patients with ES-SCLC. 90% of all patients with ES-SCLC will receive at least one of these regimens
- The result show reductions in the incidence and duration of severe neutropenia- positive impact on RBC transfusions and other myeloprotective measures- and impacted anemia and the need for rescue interventions such as growth factors
- Trilaciclib is the 1st therapy designed to help protect bone marrow during CT and has received the US FDA’s BTD in 2019 and expected to be commercially available in Mar’2021
Ref: Globenewswire | Image: Linkedin
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
